Notably, the level of Src and/or Yes tumour activity is a marker of bad prognosis and therapeutic resistance in stage IV CRC [49,55], while excessive Hck in tumour leukocytes was associated poorer CRC survival [48]. Here, YES1 is linked to neoplasm.